- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03535545
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer Patients Undergoing Radiation Therapy Prior to the Resection of Locally Advanced Tumors, and Idiopathic Pulmonary Fibrosis Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators have developed [68Ga]CBP8, a gallium-68 labeled collagen binding PET imaging probe, which selectively binds collagen type I. Collagen deposition is a pivotal event in several human conditions including pulmonary fibrosis. The investigator's studies in mice showed that [68Ga]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles with high target uptake and low retention in background tissues and organs. [68Ga]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis. [68Ga]CBP8 showed high specificity for pulmonary fibrosis and high target:background ratios in diseased animals. In addition, [68Ga]CBP8 could be used to monitor response to treatment. Ex vivo analysis of lung tissue from patients with IPF supported the animal findings.
The investigators thus aim to perform the first in human studies of [68Ga]CBP8:
- To evaluate the safety of [68Ga]CBP8 and its whole body distribution, metabolism, pharmacokinetics, and radiation burden in healthy volunteers.
- To establish the accuracy of [68Ga]CBP8-PET to detect radiation-induced fibrosis in lung cancer patients and correlate collagen-targeted [68Ga]CBP8-PET imaging with HRCT and histology in lung cancer patients.
- To determine whether collagen deposition as assessed by [68Ga]CBP8-PET molecular imaging can predict disease progression in IPF patients and patients with other types of ILD with a fibrotic component.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Sydney B Montesi, MD
- Phone Number: 617 724 4030
- Email: sbmontesi@partners.org
Study Contact Backup
- Name: Layla Rahimi
- Phone Number: 617 724 5548
- Email: Layla.Rahimi@MGH.HARVARD.EDU
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Sydney Montesi, MD
-
Principal Investigator:
- Sydney Montesi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: Total enrollment for all groups will not exceed 100 subjects.
- Group 1: Healthy subjects
- Age greater than 18 years
- Be deemed healthy at screening visit as determined by the physician investigator or nurse practitioner, based on the following assessments at Screening: physical examination, medical history, and vital signs
- Have the ability to give written informed consent;
- No known history of pulmonary disease (excluding pulmonary nodules);
- No prior history of tobacco use.
Group 2: Lung cancer subjects
- Eligible patients will be those harboring locally advanced clinical stage IIIA NSCLC who are deemed candidates for multi-modality therapy, i.e. concurrent chemotherapy and radiation followed by pulmonary resection.
- Age greater than 18 years
- Have the ability to give written informed consent.
- No tobacco use within the prior 6 months.
Group 3: Subjects with pulmonary fibrosis
- IPF (with a UIP or probable UIP pattern); or other forms of interstitial lung disease (ILD), including CTD-ILD, with a fibrotic component as noted by the presence of reticular markings and / or traction bronchiectasis and / or honeycombing on CT;
- Age: 40-80 years old;
- Have the ability to give written informed consent;
- No tobacco use within the prior 6 months
Exclusion Criteria:
- Electrical implants such as cardiac pacemaker or perfusion pump;
- Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing;
- eGFR of less than 30 mL/min/1.73 m2 within the past 90 days;
- Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate);
- Claustrophobic reactions;
- Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months);
- Unable to lie comfortably on a bed inside the MR-PET;
- BMI > 33 (limit of the MRI table);
- Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures);
- Known history of pulmonary disease (except for pulmonary fibrosis in the study group), recent pneumonia or respiratory tract infections within 6 weeks of enrollment, prior radiation therapy to the thorax (except for the lung cancer patients in aim 2);
- Pneumonia or other acute respiratory illness within 6 weeks of study entry (except for pulmonary fibrosis), pneumonia defined with elevated WBC, fever, infiltrate on CXR and need for antibiotics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy Individuals
Healthy volunteers will receive [68Ga]CBP8 and undergo PET imaging.
|
Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
All subjects will undergo PET imaging after administration of [68Ga]CBP8.
|
Experimental: Lung Cancer Subjects
Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging.
|
Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
All subjects will undergo PET imaging after administration of [68Ga]CBP8.
|
Experimental: Pulmonary Fibrosis Subjects
Idiopathic pulmonary fibrosis patients or patients with other types of interstitial lung disease with a fibrotic component will receive [68Ga]CBP8 and undergo PET imaging.
|
Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
All subjects will undergo PET imaging after administration of [68Ga]CBP8.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability to detect increased collagen deposition in pulmonary fibrosis.
Time Frame: Two hours
|
Probe lung uptake will be measured in pulmonary fibrosis subjects and compared to lung uptake in healthy volunteers.
We expect greater uptake in the lungs of IPF patients and patients with other types of ILD with a fibrotic component.
|
Two hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability of the degree of collagen deposition to predict disease progression.
Time Frame: Up to 36 months
|
Probe lung uptake in pulmonary fibrosis patients will be correlated with change in forced vital capacity over the prior 12 months and prospectively over the following 12-36 months.
|
Up to 36 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury.
Time Frame: Up to 3 months
|
Probe lung uptake will be measured in lung cancer patients prior to surgical resection and compared to histologic measures of fibrosis.
|
Up to 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sydney B Montesi, MD, Massachusetts General Hospital
Publications and helpful links
General Publications
- Desogere P, Tapias LF, Rietz TA, Rotile N, Blasi F, Day H, Elliott J, Fuchs BC, Lanuti M, Caravan P. Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis. J Nucl Med. 2017 Dec;58(12):1991-1996. doi: 10.2967/jnumed.117.193532. Epub 2017 Jun 13.
- Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017 Apr 5;9(384):eaaf4696. doi: 10.1126/scitranslmed.aaf4696.
- Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019 Jul 15;200(2):258-261. doi: 10.1164/rccm.201903-0503LE. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017P002718
- R01HL131907 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingIdiopathic Pulmonary Fibrosis | Pulmonary Disease | Pulmonary MedicineFrance
-
Centre Hospitalier Universitaire de NiceRecruitingPulmonary Disease, Chronic Obstructive | Interstitial Pulmonary FibrosisFrance
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Boehringer IngelheimNot yet recruitingIdiopathic Pulmonary Fibrosis | Progressive Pulmonary Fibrosis
Clinical Trials on [68Ga]CBP8
-
Massachusetts General HospitalNational Cancer Institute (NCI)RecruitingLung Cancer | Pancreas Cancer | Radiation Fibrosis | Radiation Induced Lung InjuryUnited States
-
Brigham and Women's HospitalRecruiting
-
Massachusetts General HospitalBoehringer IngelheimRecruitingInterstitial Lung DiseaseUnited States
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
PentixaPharm GmbHTerminated
-
Yusuf MendaNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden...Active, not recruiting
-
Peking University Cancer Hospital & InstitutePeking University Health Science CenterRecruiting
-
Xiangya Hospital of Central South UniversityCompleted
-
First Affiliated Hospital of Fujian Medical UniversityCompletedTumor Positron-Emission TomographyChina